title: Flaws in the trial design of IFCT-0802.
authors.affiliation: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. Electronic address: bg.bishalgyawali@gmail.com.
authors.forename: B
authors.initials: B
authors.lastname: Gyawali
authors.affiliation: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shimokata
authors.affiliation: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Honda
authors.affiliation: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ando
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab